TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06742710
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1500 mg/day until pregnancy
Study: NCT06742086
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablet
Study: NCT04646005
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously (IV) every three weeks (Q3W)
Study: NCT06732401
Drug: Ceralasertib
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06742333
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12
Study: NCT06742333
Drug: Clobetasol
Normalized name: Clobetasol
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks
Study: NCT06741085
Drug: osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral EGFR-TKI
Study: NCT05999487
Drug: Dobutamine
Normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient randomization will be done by a computer based generation , serial enveloped numbers will be taken for the patients. Cardiac assessment will be done by a blinded pediatric cardiologist. If at any time the randomly assigned therapy considered to be failed or unsafe to continue, the treating physician will discontinue randomization and will continue with the appropriate medication according to the patients need.~Milrinone will start by 0.25 , 0.5 , 0.75 we can titrate up with time interval 3 hours after re-assessment.~Dobutamine will start by 5, 10 , 15, 20 we can titrate with time interval 15 mins after re-assesment.
Study: NCT05939037
Drug: Zanubrutinib Oral Product
Normalized name: zanubrutinib Oral Product
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands.
Study: NCT06737016
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).
Study: NCT06737016
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.
Study: NCT06737016
Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.
Study: NCT05466799
Drug: FOLFIRINOX chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
Study: NCT06142474
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group
Study: NCT06750588
Drug: bacteriophage preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTR-101 will be given orally to participants once daily for 7 days
Study: NCT06750588
Drug: Bacteriophage preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTR-101 will be given orally to participants once daily for 7 days
Study: NCT06750588
Drug: bacteriophage preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTR-101 will be given orally to participants twice daily for 7 days
Study: NCT06750588
Drug: bacteriophage preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTR-101 will be given orally to participants three times daily for 7 days
Study: NCT06750861
Drug: QL1706
Normalized name: QL1706
DrugBank: QL1706 (DB17562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1706+AG
Study: NCT06744894
Drug: Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.
Study: NCT06742567
Drug: Apixaban 2.5 MG PO BID
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT.
Study: NCT06742567
Drug: Control (Standard treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DAPT plus guideline directed medical therapy
Study: NCT05009017
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
Study: NCT02666209
Drug: Ulocuplumab
Normalized name: Ulocuplumab
DrugBank: Ulocuplumab (DB12018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCR4 inhibitor given weekly on a 28 day cycle intravenously
Study: NCT06741553
Drug: Lecanemab 10 mg/kg
DrugBank: Lecanemab (DB14580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecanemab was administered 10mg/kg every two weeks.
Study: NCT02666209
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
Study: NCT02666209
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
Study: NCT02666209
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: steroid given at physician discretion on a 28 day cycles
Study: NCT04877821
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg on days 1 (Q3W) of the neoadjuvant and adjuvant phase of the study; IV injection.
Study: NCT04877821
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12mg on d1-14 of Cycles 1-8 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
Study: NCT04877821
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m² on day 1, 8 and 15 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
Study: NCT04877821
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 on days 1 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
Study: NCT04877821
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
Study: NCT06741722
Drug: Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The specific administration times and dosages for the DCMG chemotherapy regimen are as follows:~M: Mitoxantrone Hydrochloride Liposome Injection: 15 mg/m², IV, on Day 1, every 4 weeks (q4w); D: Decitabine: 20 mg/m², IV, Days 1-5, q4w; (or Azacitidine: 75 mg/m², IV, Days 1-7, q4w); C: Cytarabine: 100 mg, IV, every 12 hours on Days 1-5, q4w; For patients with hypoplastic bone marrow, the dose of cytarabine injection is 10 mg, every 12 hours, q4w; G: G-CSF: 5 μg/kg, subcutaneous injection, from Day 0 until the white blood cell count exceeds 10.0×10\^9/L, at which point chemotherapy is stopped; or Pegylated Recombinant Human Granulocyte Stimulating Factor Injection: 100 μg/kg, subcutaneous injection, on Day 0.~One cycle lasts for 4 weeks, with a planned administration of 1 or 2 cycles.
Study: NCT06748144
Drug: Intraosseous Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention is specific to the method of administration that will be used when giving the dose of antibiotic vancomycin which is done to prevent infection following surgery.
Study: NCT06748144
Drug: Intravenous Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is the standard method of giving the antibiotic vancomycin to patients undergoing surgery across many specialties in order to prevent infection.
Study: NCT06747130
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Study: NCT06747130
Drug: Montelukast Placebo
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
Study: NCT06746441
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin is a naturally occurring serotonergic psychedelic compound found in Psilocybe mushrooms. It is metabolized in the body into its active form, psilocin, which has a high affinity for serotonin 5-HT2A receptors. This enables psilocin to bypass the default serotonin pathway, producing antidepressant effects.~For this study:~Psilocybin will be administered orally in a dose of 5-6 grams per session. Each participant in the Psilocybin and Psilocybin-assisted CBT arms will receive two sessions spaced six weeks apart.~The therapy will be conducted in a controlled hospital setting with medical monitoring during the session to ensure safety until the hallucination phase subsides.~Psilocybin will be added to routine antidepressant medication.
Study: NCT06747312
Drug: Belimumab+SOC
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg/kg once a month for 18 months
Study: NCT05906524
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab will be administered intravenously.
Study: NCT05906524
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered intravenously.
Study: NCT06780826
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle
Study: NCT06780826
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide,intravenous infusion, 100mg/m,21 days per cycle
Study: NCT06780826
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin,intravenous infusion, AUC=5, 21 days per cycle.
Study: NCT05217927
Drug: Rimegepant 75mg daily dosing
Normalized name: rimegepant 75 MG
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily
Study: NCT05217927
Drug: Rimegepant 75mg every other day dosing
Normalized name: rimegepant 75 MG
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every other day
Study: NCT06784336
Drug: Potato Resistant Starch
Normalized name: Potato Starch
DrugBank: Potato (DB10562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive PRS beginning on day -6 and continuing through day +100. Patients will take 20g packet twice daily
Study: NCT06736860
Drug: Tranexamic acid (TXA) injection
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. The 1+1 control group continued to infuse 1g TXA within 8 h.
Study: NCT06736860
Drug: Tranexamic acid (TXA) injection
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. the 1+x study group was subjected to thromboelastography (TEG) without TXA for the time being, and the coagulation and fibrinolytic status of the patients was judged according to the results of TEG (LY30, EPL value), and the patients diagnosed with hyperfibrinolysis continued to be infused with 1g TXA, and the patients diagnosed with normal or reduced fibrinolysis were not infused with TXA. TEG was rechecked after 4 h, and the decision of whether to use TXA was based on the TEG results.
Study: NCT06785415
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06785415
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06786533
Drug: Anti-FLT3 CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.
Study: NCT00002212
Drug: Bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06667687
Drug: ABBV-291
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT06747559
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D oral supplementation
Study: NCT06747507
Drug: Dolutegravir Pill
Normalized name: dolutegravir Pill
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose will be based on weight; brand names will be as supplied through the respective national programs
Study: NCT05198180
Drug: Topical 30%Potassium hydroxide solution
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will apply the solution every day under occlusion for 3 months
Study: NCT05198180
Drug: Topical 45% hydrogen peroxide solution
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will apply the solution every day under occlusion
Study: NCT04860674
Drug: PD-1 inhibitor +ICE
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen
Study: NCT06747507
Drug: Darunavir+Ritonavir
Normalized name: Darunavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose will be based on weight
Study: NCT06746545
Drug: Fruquintinib+S-1
Normalized name: fruquintinib 1 MG
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib: 5 mg, oral, once daily，2w/1w；Q3W S-1：40-60 mg (dosed according to body surface area), oral，2w/1w；Q3W
Study: NCT06501326
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
Study: NCT06501326
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
Study: NCT05031494
Drug: YH003
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
Study: NCT05031494
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab will be administered at a dose of 240 mg every 3 weeks.
Study: NCT05031494
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered each 21-day cycle.
Study: NCT05031494
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administrated each 21-day cycle.
Study: NCT06004791
Drug: Herombopag + CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
Study: NCT06004791
Drug: rhTPO combined with Herombopag + CsA
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rhTPO (15000U, subcutaneous injection, once a day for 7 days, once a month for 3 months)，Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
Study: NCT05435846
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT05435846
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT06750458
Drug: Dapagliflozin placebo
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dapagliflozin 10 mg once daily for 14 days pre-operative
Study: NCT06750458
Drug: DexamethasoneGroup III (n=25) (Dexamethasone group)
Normalized name: dexamethasone 0.25 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.
Study: NCT04181606
Drug: Esmolol infusion
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).
Study: NCT06748937
Drug: Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD
Normalized name: ethionamide 125 MG
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1 Arm 1
Study: NCT06748937
Drug: Alpibectir 45 mg OD plus Ethionamide 250 mg OD
Normalized name: ethionamide 250 MG
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 1 Arm 2
Study: NCT06748937
Drug: Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT06748937
Drug: Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort 2 Arm 4
Study: NCT04809584
Drug: F18-DCFPyL
Normalized name: F18-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will be injected iv with 9 mCi ± 20% of 18F-DCFPyL
Study: NCT04809584
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast agent
Study: NCT06571422
Drug: JS001+Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in Cohort1 of combination therapy phase will receive WJ47156 plus toripalimab and bevacizumab.Toripalimab and bevacizumab are administered intravenously.
Study: NCT06571422
Drug: JS207
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in Cohort2 of combination therapy phase will receive WJ47156 plus JS207. JS207 is administered intravenously.
Study: NCT06578728
Drug: Triamcinolone Acetonide 10mg/mL
Normalized name: TRIAMCINOLONE ACETONIDE 10MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/mL intralesional injection into nail bed/nail matrix
Study: NCT06578728
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline intralesional injection into nail bed/nail matrix